Clinical and molecular aspects of retinoid therapy for acute promyelocytic leukemia.
As a single agent, all-trans RA produces a higher rate of complete remission in APL than any other drug in any other neoplastic disease. The molecular findings in this illness have been exploited to develop a means of detecting and eradicating minimal residual disease. Compared with other forms of acute myeloid leukemia, this subtype is now associated with the highest proportion of patients in extended disease-free first remission who are presumably cured of their disease. APL is a prototype for understanding the pathogenesis of a malignant disease and the development of novel therapies that are targeted to specific molecular abnormalities.
Warrell
R P
RP
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D016133:Polymerase Chain Reaction; D012074:Remission Induction; D014212:Tretinoin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014212:Tretinoin